Cebu Pacific Back To Full Year Profit After Pandemic Losses

Cebu Pacific soars to new heights with Php 90.6 billion in revenue for 2023, marking a 60% increase from the previous year!

FDA DG Assists Small Businesses With BBMSME Program, Joins First Lady in Tuguegarao

Food and Drug Administration Director General Dr. Samuel Zacate partners with Tuguegarao Mayor to empower local entrepreneurs through Bigyan-Halaga, Bangon Micro, Medium and Small Enterprises program.

Tala’s Iona Inigo-Mayo Shares Its Empowerment On The Organization And Its Customers

Gender-inclusive workplaces drive success! Tala empowers women, fostering leadership & financial independence, transforming lives and communities globally.

HONOR PH Introduces HONOR X7b, Another High-Quality Phone Without Breaking Your Wallet

HONOR Philippines locally debuts the durable, budget-friendly HONOR X7b, boasting impressive features like extended battery life and superb display.

Vaccine Booster Restores Full Protection Vs. Covid-19: Pfizer

0

Vaccine Booster Restores Full Protection Vs. Covid-19: Pfizer

0

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Pfizer and BioNTech announced Thursday that a large-scale trial of their coronavirus disease 2019 (Covid-19) vaccine booster showed it restored full protection against the disease.

In Phase 3 randomized, controlled trial, a Pfizer-BioNTech booster dose was administered to more than 10,000 individuals 16 years of age and older, who previously received the Pfizer-BioNTech primary two-dose series.

It showed relative vaccine efficacy of 95.6 percent when compared to those who did not receive a booster.

These are the first efficacy results from any randomized, controlled Covid-19 vaccine booster trial.

“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Albert Bourla, Pfizer chairman and chief executive officer.

Last month, the U.S. Food and Drug Administration authorized the booster shots for the Pfizer-BioNTech Covid-19 vaccine, allowing a single booster dose of it to be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. (PNA)